zacks.com / Page 6

AZN's key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, are expected to have driven the company's top line.

MainStreet Bank (MNSB) delivered earnings and revenue surprises of 19.05% and 1.39%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

TYL's Q1 results are likely to reflect benefits from robust demand for SaaS solutions as the public sector shifts from on-premise to cloud-based systems.

Universal Technical (UTI) could produce exceptional returns because of its solid growth attributes.

MasTec (MTZ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does NatWest Group (NWG) have what it takes? Let's find out.

Gentex (GNTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Recently, Zacks.com users have been paying close attention to IBM (IBM). This makes it worthwhile to examine what the stock has in store.

Market corrections are opportunities in disguise... and this one is no exception. Kevin Matras highlights several reasons why 2025 is still poised to be a historic bull market and shows how you can take part in the spectacular rebound ...